BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/12/2024 10:04:16 AM | Browse: 141 | Download: 327
 |
Received |
|
2023-11-01 12:58 |
|
Peer-Review Started |
|
2023-11-01 12:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-06 00:24 |
|
Revised |
|
2023-12-14 07:10 |
|
Second Decision |
|
2024-01-18 02:54 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-01-18 05:23 |
|
Articles in Press |
|
2024-01-18 05:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-02-19 03:33 |
|
Publish the Manuscript Online |
|
2024-03-12 10:04 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qiu-Yu Jiang and Ru-Yi Xue |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ru-Yi Xue, MD, PhD, Chief Physician, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai Institute of Liver Disease, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xue.ruyi@zs-hospital.sh.cn |
| Key Words |
Immune-related adverse event; Immune-checkpoint inhibitor; Platelet-to-lymphocyte ratio; Neutrophil-to-lymphocyte ratio |
| Core Tip |
The negative correlation between high baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) and the effectiveness of immune-checkpoint inhibitor (ICI) treatment has been confirmed in non-small cell lung cancer, melanoma, and hepatocellular carcinoma. However, there is a scarcity of studies investigating the prediction of immune-related adverse events (irAEs) occurrence. By incorporating NLR and PLR with other potential risk factors, it is possible to enhance the predictive accuracy of both ICI response and irAEs occurrence through the development of joint prediction models. This approach can aid in the selection of appropriate candidates for ICIs. |
| Publish Date |
2024-03-12 10:04 |
| Citation |
Jiang QY, Xue RY. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events. World J Gastrointest Oncol 2024; 16(3): 577-582 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i3/577.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i3.577 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
